Lydia Emerson
lydia emerson

Dr Lydia Emerson

Senior Research Fellow

  L.Emerson@napier.ac.uk

   

Biography

Lydia is a critical care researcher who joined Edinburgh Napier University as a Senior Research Fellow in 2023.

She was awarded a prestigious four-year PhD fellowship by the Medical Research Council (MRC) Network of Hubs for Trials Methodology Research, which she undertook at Queen's University Belfast. The focus of this work was to develop framework guidance for conducting process evaluations within complex critical care trials.

Lydia's research interests remain in clinical trials methodology, with a specific focus on process evaluation of complex intervention trials in critical care. Lydia is highly experienced in the design and conduct of process evaluations within the intensive care unit setting, and has been involved in the design and delivery of several large UK-wide randomised controlled trials.

School

Esteem

Fellowships and Awards

  • PhD Fellow: Medical Research Council (Network of Hubs for Trials Methodology Research)

 

Filter by

Date


4 results

Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B trial): protocol for a mixed-methods process evaluation of a randomised controlled trial

Journal Article
Aitken, L. M., Emerson, L. M., Kydonaki, K., Blackwood, B., Creagh-Brown, B., Lone, N. I., …Walsh, T. S. (2024)
Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B trial): protocol for a mixed-methods process evaluation of a randomised controlled trial. BMJ Open, 14(4), Article e081637. https://doi.org/10.1136/bmjopen-2023-081637
Introduction: An association between deep sedation and adverse short-term outcomes has been demonstrated although this evidence has been inconsistent. The A2B (alpha-2 agonist...

Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK

Journal Article
Walsh, T. S., Aitken, L. M., McKenzie, C. A., Boyd, J., Macdonald, A., Giddings, A., …Page, V. J. (2023)
Alpha 2 agonists for sedation to produce better outcomes from critical illness (A2B Trial): protocol for a multicentre phase 3 pragmatic clinical and cost-effectiveness randomised trial in the UK. BMJ Open, 13(12), Article e078645. https://doi.org/10.1136/bmjopen-2023-078645
Introduction: Almost all patients receiving mechanical ventilation (MV) in intensive care units (ICUs) require analgesia and sedation. The most widely used sedative drug is pr...

Correction: Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the Role of Active Deresuscitation Correction: After Resuscitation-2 (RADAR-2) randomised clinical trial

Journal Article
Silversides, J. A., McMullan, R., Emerson, L. M., Bradbury, I., Bannard-Smith, J., Szakmany, T., …McAuley, D. F. (2023)
Correction: Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the Role of Active Deresuscitation Correction: After Resuscitation-2 (RADAR-2) randomised clinical trial. Intensive Care Medicine, 49(11), 1440-1440. https://doi.org/10.1007/s00134-023-07174-w

Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the Role of Active Deresuscitation After Resuscitation-2 (RADAR-2) randomised clinical trial

Journal Article
Silversides, J. A., McMullan, R., Emerson, L. M., Bradbury, I., Bannard-Smith, J., Szakmany, T., …McAuley, D. F. (2022)
Feasibility of conservative fluid administration and deresuscitation compared with usual care in critical illness: the Role of Active Deresuscitation After Resuscitation-2 (RADAR-2) randomised clinical trial. Intensive Care Medicine, 48(2), 190-200. https://doi.org/10.1007/s00134-021-06596-8
Purpose Fluid overload is common in critical illness and is associated with mortality. This study investigated the feasibility of a randomised trial comparing conservative flu...